smjournalСпортивная медицина: наука и практикаSports medicine: research and practice2223-25242587-9014NEICON10.47529/2223-2524.2021.4.3smjournal-343Research ArticleВРАЧЕБНЫЙ КОНТРОЛЬMEDICAL CONTROLПриобретенное удлинение интервала QT у спортсменовAcquired long QT interval in athletesЮнисоваА. С.YunisovaA. S.

Юнисова Алина Саидовна, аспирант кафедры спортивной медицины

105122, Россия, Москва, Сиреневый бульвар, 4

Alina S. Yunisova — M.D., Graduate student of the Department of Sports Medicine

4, Sirenevyi blvd., Moscow, 105122, Russia

yunisova.alina@yandex.ruСмоленскийА. В.SmolenskyA. V.

Смоленский Андрей Вадимович, д.м.н., профессор, заведующий кафедрой спортивной медицины

105122, Россия, Москва, Сиреневый бульвар, 4

Andrey V. Smolensky — M.D., D.Sc. (Medicine), Head of the Department of Sports Medicine

4, Sirenevyi blvd., Moscow, 105122 Russia

smolensky52@mail.ruФГБОУ ВО «Российский государственный университет физической культуры, спорта, молодежи и туризма»РоссияRussian State University of Physical Culture, Sports, Youth and TourismRussian Federation2021050520221141725Copyright © Юнисова А.С., Смоленский А.В., 20222022Юнисова А.С., Смоленский А.В.Yunisova A.S., Smolensky A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.smjournal.ru/jour/article/view/343

Синдром удлиненного синдрома QT (LQTS) — часто встречаемое нарушение состояния, приводящее к драматичным для пациентов исходам, главным из которых является внезапная сердечная смерть. В данном обзоре представлены подробные данные о диагностике, распространенности, классификации, этиологии. Многообразие причин, приводящих к LQTS, создает сложности в дифференциальной диагностике этого состояния, и в итоге LQTS часто остается за пределами внимания врачей, осуществляющих контроль состояния здоровья спортсменов. Особое внимание уделено приобретенным формам LQTS, в частности лекарственно­индуцированной форме. Изложены результаты исследований, направленных на изучение распространенности LQTS и влияние лекарственных препаратов на интервал QT. Подробно рассмотрено влияние на интервал QT нестероидных противовоспалительных средств, поскольку они часто используются спортсменами. Цель данного обзора — расширить понимание этиологии LQTS и обосновать необходимость тщательного ЭКГ­скрининга и фармакологического контроля у спортсменов.

Long QT syndrome (LQTS) is a common disorder that leads to dramatic patient outcomes, chief among which is sudden cardiac death. This review provides detailed data on the diagnosis, prevalence, classification, etiology. The variety of causes leading to LQTS creates difficulties in the differential diagnosis of this condition and, as a result, LQTS often remains outside the attention of physicians who monitor the health of athletes. Particular attention is paid to the acquired forms of LQTS, particularly, the drug-induced form. The results of studies aimed at studying the prevalence of LQTS and the effect of drugs on the QT interval are presented. The influence of non-steroidal anti-inflammatory drugs on the QT interval is discussed in detail because they are often used by athletes. The purpose of this review is to expand understanding of the etiology of LQTS and justify the need for careful ECG screening and pharmacological monitoring in athletes.

интервал QTвнезапная сердечная смертьлекарственно­индуцированный LQTSспортсменыQT intervalsudden cardiac deathdrug-induced LQTSathletesReferencesAckerman M.J., Priori S.G., Willems S., Berul C., Brugada R., Calkins H., et al. HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: Tis document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13(8):1077–1109. https://doi.org/10.1093/europace/eur245Ackerman M.J., Priori S.G., Willems S., Berul C., Brugada R., Calkins H., et al. HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace. 2011;13(8):1077–1109. https://doi.org/10.1093/ europace/eur245Ackerman M.J. Long QT syndrome and sports participation: oil and water or an acceptable and manageable combination? JACC Clin. Electrophysiol. 2015;1(1–2):71–73. https://doi.org/10.1016/j.jacep.2015.03.009Ackerman M.J. Long QT syndrome and sports participation: oil and water or an acceptable and manageable combination? JACC Clin. Electrophysiol. 2015;1(1–2):71–73. https://doi.org/10.1016/j.jacep.2015.03.009Adler A., vander Werf C., Postema P.G., Rosso R., Bhuiyan Z.A., Kalman J.M., et al. Tephenomenon of ‘QT stunning’: Te abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm. 2012;9(6):901–908. https://doi.org/10.1016/j.hrthm.2012.01.026Adler A., vander Werf C., Postema P.G., Rosso R., Bhuiyan Z.A., Kalman J.M., et al. Thephenomenon of ‘QT stunning’: The abnormal QT prolongation provoked by standing persists even as the heart rate returns to normal in patients with long QT syndrome. Heart Rhythm. 2012;9(6):901–908. https://doi.org/10.1016/j.hrthm.2012.01.026Bazett H.C. An analysis of time­relations of electrocardiograms. Heart. 1920;7:353–370.Bazett H.C. An analysis of time-relations of electrocardiograms. Heart. 1920;7:353–370.Border W.L., Benson D.W. Sudden infant death syndrome and long QT syndrome: the zealots versus the naysayers. Heart Rhythm. 2007;4(2):167–169. https://doi.org/10.1016/j.hrthm.2006.12.019Border W.L., Benson D.W. Sudden infant death syndrome and long QT syndrome: the zealots versus the naysayers. Heart Rhythm. 2007;4(2):167–169. https://doi.org/10.1016/j.hrthm.2006.12.019Klivinyi C., Bornemann-Cimenti H. Pain medication and long QT syndrome. Korean J. Pain. 2018;31(1):3–9. https://doi.org/10.3344/kjp.2018.31.1.3Klivinyi C., Bornemann-Cimenti H. Pain medication and long QT syndrome. Korean J. Pain. 2018;31(1):3–9. https://doi.org/10.3344/kjp.2018.31.1.3Corrado D., Basso C., Pavei A., Michieli. P., Schiavon M., Tiene G. Trends in sudden cardiovascular death in young competitive athletes afer implementation of a preparticipation screening program. JAMA. 2006; 296(13):1593–1601. https://doi.org/10.1001/jama.296.13.1593Corrado D., Basso C., Pavei A., Michieli P., Schiavon M., Thiene G. Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program. JAMA. 2006; 296(13):1593–1601. https://doi.org/10.1001/jama.296.13.1593Corrado D., Pelliccia A., Bjornstad H.H., Vanhees L., Biffi A., Borjesson M., et al. Cardiovascular pre­participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Eur. Heart J. 2005;26(5): 516–524. https://doi.org/10.1093/eurheartj/ehi108Corrado D., Pelliccia A., Bjornstad H.H., Vanhees L., Biffi A., Borjesson M., et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Eur. Heart J. 2005;26(5): 516–524. https://doi.org/10.1093/eurheartj/ehi108Corrado D., Basso C., Schiavon M., Tiene G. Screening for hypertrophic cardiomyopathy in young athletes. N. Eng. J. Med. 1998;339(6):364–369. https://doi.org/10.1056/NEJM199808063390602Corrado D., Basso C., Schiavon M., Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N. Eng. J. Med. 1998;339(6):364–369. https://doi.org/10.1056/NEJM199808063390602Pelliccia A., Sharma S., Gati S., Bäck M., Börjesson M., Caselli S., et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur. Heart J. 2021;42(1):17–96. https://doi.org/10.1093/eurheartj/ehaa605Pelliccia A., Sharma S., Gati S., Bäck M., Börjesson M., Caselli S., et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur. Heart J. 2021;42(1):17–96. https://doi.org/10.1093/eurheartj/ehaa605Digby G.C., Perez Riera A.R., Barbosa Barros R., Simpson C.S., Redfearn D.P., Methot M., et al. Acquired Long QT Interval: A Case Series of Multifactorial QT Prolongation. Clin. Cardiol. 2011;34(9):577–582. https://doi.org/10.1002/clc.20945Digby G.C., Perez Riera A.R., Barbosa Barros R., Simpson C.S., Redfearn D.P., Methot M., et al. Acquired Long QT Interval: A Case Series of Multifactorial QT Prolongation. Clin. Cardiol. 2011;34(9):577–582. https://doi.org/10.1002/clc.20945Mantovani G. Pseudohypoparathyroidism: Diagnosis and Treatment. J. Clin. Endocrinol. Metab. 2011;96(10):3020–3030. https://doi.org/10.1210/jc.2011­1048Mantovani G. Pseudohypoparathyroidism: Diagnosis and Treatment. J. Clin. Endocrinol. Metab. 2011;96(10):3020–3030. https://doi.org/10.1210/jc.2011-1048Meyer T., Ruppert V., Karatolios K., Maisch B. Hereditary long QT syndrome due to autoimmune hypoparathyroidism in autoimmune polyendocrinopathy­candidiasis­ectodermal dystrophy syndrome. J. Electrocardiol. 2007;40(6):504–509. https://doi.org/10.1016/j.jelectrocard.2006.12.013Meyer T., Ruppert V., Karatolios K., Maisch B. Hereditary long QT syndrome due to autoimmune hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. J. Electrocardiol. 2007;40(6):504–509. https://doi.org/10.1016/j.jelectrocard.2006.12.013Michels G., Kochanek M., Pfster R. Life­threatening cardiac arrhythmias due to drug­induced QT prolongation. Med. Klin. Intensivmed. Notfmed. 2016;111(4):302–309. https://doi.org/10.1007/s00063­015­0071­6Michels G., Kochanek M., Pfister R. Life-threatening cardiac arrhythmias due to drug-induced QT prolongation. Med. Klin. Intensivmed. Notfmed. 2016;111(4):302–309. https://doi.org/10.1007/s00063-015-0071-6Mitchell J.H., Haskell W.L., Raven P.B. Classifcation of sports. J. Am. Coll Cardiol. 1994; 24(4):864–866. https://doi.org/10.1016/0735­1097(94)90841­9Mitchell J.H., Haskell W.L., Raven P.B. Classification of sports. J. Am. Coll Cardiol. 1994;24(4):864–866. https://doi.org/10.1016/0735-1097(94)90841-9Molokhia M., Pathak A., Lapeyre-Mestre M., Caturla L., Montastruc J L., L’Association Française des Centres Régionaux de Pharmacovigilance (CRPV), ase ascertainment and estimated incidence of drug­induced long­QT syndrome: Study in Southwest France. Br. J. Clin Pharmacol. 2008;66(3):386–395. https://doi.org/10.1111/j.1365­2125.2008.03229.xMolokhia M., Pathak A., Lapeyre-Mestre M., Caturla L., Montastruc J. L. L’Association Française des Centres Régionaux de Pharmacovigilance (CRPV), McKeigue P. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: Study in Southwest France. Br. J. Clin Pharmacol. 2008;66(3):386–395. https://doi.org/10.1111/j.1365-2125.2008.03229.xMoss A.J. Long QT syndrome. JAMA. 2003;289(16):2041–2044. https://doi.org/10.1001/jama.289.16.2041Moss A.J. Long QT syndrome. JAMA. 2003;289(16):2041–2044. https://doi.org/10.1001/jama.289.16.2041Moss A.J., Schwartz P.J., Crampton R.S., Tzivoni D., Locati E.H., MacCluer J., et al. Te long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991;84(3):1136–1144. https://doi.org/10.1161/01.cir.84.3.1136Moss A.J., Schwartz P.J., Crampton R.S., Tzivoni D., Locati E.H., MacCluer J., et al. The long QT syndrome. Prospective longitudinal study of 328 families. Circulation. 1991;84(3):1136–1144. https://doi.org/10.1161/01.cir.84.3.1136Napolitano C., Priori S.G., Schwartz P.J., Bloise R., Ronchetti E., Nastoli J., et al. Genetic testing in the long QT syndrome: development and validation of an efcient approach to genotyping in clinical practice. JAMA. 2005;294(23):2975–2980. https://doi.org/10.1001/jama.294.23.2975Napolitano C., Priori S.G., Schwartz P.J., Bloise R., Ronchetti E., Nastoli J., et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005;294(23):2975–2980. https://doi.org/10.1001/jama.294.23.2975Newman D.B., Fidahussein S.S., Kashiwagi D.T., Kennel K.A., Kashani K.B., Zhen Wang, et al. Reversible cardiac dysfunction asso­ciated with hypocalcemia: a systematic review and metaanalysis of individual patient data. Heart Fail. Rev. 2014;19(2):199–205. https://doi.org/10.1007/s10741­013­9371­1Newman D.B., Fidahussein S.S., Kashiwagi D.T., Kennel K.A., Kashani K.B., Zhen Wang, et al. Reversible cardiac dysfunction asso-ciated with hypocalcemia: a systematic review and meta-analysis of individual patient data. Heart Fail. Rev. 2014;19(2):199–205. https://doi.org/10.1007/s10741-013-9371-1Pathak A., Boveda S., Defaye P., Mansourati J., Mallaret M., Tebault L., et al. Celecoxib­associated torsade de pointes. Ann Pharmacother. 2002;36(7–8):1290–1291. https://doi.org/10.1345/aph.1A429Pathak A., Boveda S., Defaye P., Mansourati J., Mallaret M., Thebault L., et al. Celecoxib-associated torsade de pointes. Ann Pharmacother. 2002;36(7–8):1290–1291. https://doi.org/10.1345/aph.1A429Pelliccia A., Fagard R., Bjørnstad H.H., Anastassakis A., Arbustini E., Assanelli D., et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur. Heart J. 2005;26(14):1422–1445. https://doi.org/10.1093/eurheartj/ehi325Pelliccia A., Fagard R., Bjørnstad H.H., Anastassakis A., Arbustini E., Assanelli D., et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur. Heart J. 2005;26(14):1422–1445. https://doi.org/10.1093/eurheartj/ehi325Priori S.G., Blomström-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2015;36(41):2793–2867. https://doi.org/10.1093/eurheartj/ehv316Priori S.G., Blomström-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2015;36(41):2793–2867. https://doi.org/10.1093/eurheartj/ehv316Priori S.G., Schwartz P.J., Napolitano C., Bloise R., Ronchetti E., Grillo M., et al. Risk Stratifcation in the Long­QT Syndrome. N. Engl. J. Med. 2003;348(19):1866–1874. https://doi.org/10.1056/nejmoa022147Priori S.G., Schwartz P.J., Napolitano C., Bloise R., Ronchetti E., Grillo M., et al. Risk Stratification in the Long-QT Syndrome. N. Engl. J. Med. 2003;348(19):1866–1874. https://doi.org/10.1056/nejmoa022147Priori S.G., Wilde A.A., Horie M., Cho Y., Behr E.R., Berul C., et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10(12):e85–e108. https://doi.org/10.1016/j.hrthm.2013.07.021Priori S.G., Wilde A.A., Horie M., Cho Y., Behr E.R., Berul C., et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10(12):e85–e108. https://doi.org/10.1016/j.hrthm.2013.07.021Kim J.A., Chelu M.G. Inherited Arrhythmia Syndromes. Tex Heart Inst J. 2021 Sep 1;48(4):e207482. https://doi.org/10.14503/THIJ­20­7482.Kim J.A., Chelu M.G. Inherited Arrhythmia Syndromes. Tex Heart Inst J. 2021 Sep 1;48(4):e207482. https://doi.org/10.14503/THIJ-20-7482.Nakano Y., Shimizu W. Genetics of long­QT syndrome. J. Hum. Genet. 2016;61(1):51–55. https://doi.org/10.1038/jhg.2015.74Nakano Y., Shimizu W. Genetics of long-QT syndrome. J. Hum. Genet. 2016;61(1):51–55. https://doi.org/10.1038/jhg.2015.74Rajab A., Straub V., McCann L.J., Seelow D., Varon R., Barresi R., et al. Fatal cardiac arrhythmia and long­QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF­CAVIN mutations. PLoS Genet. 2010;6(3):e1000874. https://doi.org/10.1371/journal.pgen.1000874Rajab A., Straub V., McCann L.J., Seelow D., Varon R., Barresi R., et al. Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations. PLoS Genet. 2010;6(3):e1000874. https://doi.org/10.1371/journal.pgen.1000874Roden D.M. Predicting drug­induced QT prolongation and torsades de pointes. J. Physiol. 2016;594(9):2459–68. https://doi.org/10.1113/JP270526Roden D.M. Predicting drug-induced QT prolongation and torsades de pointes. J. Physiol. 2016;594(9):2459–68. https://doi.org/10.1113/JP270526Basavarajaiah S., Wilson M., Whyte G., Shah A., Behr E., Sharma S. Prevalence and signifcance of an isolated long QT interval in elite athletes. Eur. Heart J. 2007;28(23):2944–2949. https://doi.org/10.1093/eurheartj/ehm404Basavarajaiah S., Wilson M., Whyte G., Shah A., Behr E., Sharma S. Prevalence and significance of an isolated long QT interval in elite athletes. Eur. Heart J. 2007;28(23):2944–2949. https://doi.org/10.1093/eurheartj/ehm404Schwartz P.J., Woosley R.L. Predicting the Unpredictable: Drug­Induced QT Prolongation and Torsades de Pointes. J. Am. Coll. Cardiol. 2016;67(13):1639–1650. https://doi.org/10.1016/j.jacc.2015.12.063Schwartz P.J., Woosley R.L. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J. Am. Coll. Cardiol. 2016;67(13):1639–1650. https://doi.org/10.1016/j.jacc.2015.12.063Schwartz P.J., Moss A.J., Vincent G.M., Crampton R.S. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993;88(2):782–784. https://doi.org/10.1161/01.cir.88.2.782Schwartz P.J., Moss A.J., Vincent G.M., Crampton R.S. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993;88(2):782–784. https://doi.org/10.1161/01.cir.88.2.782Schwartz P.J.,Crotti L.QTc behavior during exercise and genetic testing for the long­QT syndrome. Circulation. 2011;124(20):2181–2184. https://doi.org/10.1161/CIRCULATIONAHA.111.062182Schwartz P.J., Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011;124(20):2181–2184. https://doi.org/10.1161/CIRCULATIONAHA.111.062182Sharma S., Whyte G., Elliott P., Padula M., Kaushal R., Mahon N., McKenna W.J. Electrocardiographic changes in 1000 highly trained junior elite athletes. Br. J. Sports Med. 1999;33(5):319–324. https://doi.org/10.1136/bjsm.33.5.319Sharma S., Whyte G., Elliott P., Padula M., Kaushal R., Mahon N., McKenna W.J. Electrocardiographic changes in 1000 highly trained junior elite athletes. Br. J. Sports Med. 1999;33(5):319–324. https://doi.org/10.1136/bjsm.33.5.319Straus M., Sturkenboom M.C., Bleumink G.S., Dieleman J.P., van der Lei J., de Graeff P.A., et al. Non­cardiac QTcprolonging drugs and the risk of sudden cardiac death. Eur. Heart J. 2005;26(19):2007–2012. https://doi.org/10.1093/eurheartj/ehi312Straus M., Sturkenboom M.C., Bleumink G.S., Dieleman J.P., van der Lei J., de Graeff P.A., et al. Non-cardiac QTcprolonging drugs and the risk of sudden cardiac death. Eur. Heart J. 2005;26(19):2007–2012. https://doi.org/10.1093/eurheartj/ehi312Maury P., Delasnerie H., Beneyto M., Rollin A. Autonomic cardiac innervation: impact on the evolution of arrhythmias in inherited cardiac arrhythmia syndromes. Herzschrittmacherther Elektrophysiol. 2021 Sep;32(3):308–314. English. https://doi.org/10.1007/s00399­021­00774­3 Epub 2021 Jun 29.Maury P., Delasnerie H., Beneyto M., Rollin A. Autonomic cardiac innervation: impact on the evolution of arrhythmias in inherited cardiac arrhythmia syndromes. Herzschrittmacherther Elektrophysiol. 2021 Sep;32(3):308–314. English. https://doi.org/10.1007/s00399-021-00774-3 Epub 2021 Jun 29.Turan S. Current nomenclature of pseudohypoparathyroidism: inactivating parathyroid hormone / parathyroid hormonerelated protein signaling disorder. J. Clin. Res. Pediatr. Endocrinol. 2017;9(2):58–68. https://doi.org/10.4274/jcrpe.2017.s006Turan S. Current nomenclature of pseudohypoparathyroidism: inactivating parathyroid hormone / parathyroid hormonerelated protein signaling disorder. J. Clin. Res. Pediatr. Endocrinol. 2017;9(2):58–68. https://doi.org/10.4274/jcrpe.2017.s006Underbjerg L., Sikjaer T., Mosekilde L., Rejnmark L. Pseudohypoparathyroidism — epidemiology, mortality and risk of complications. Clin. Endocrinol (Oxf.). 2016;84(6):904–911. https://doi.org/10.1111/cen.12948Underbjerg L., Sikjaer T., Mosekilde L., Rejnmark L. Pseudohypoparathyroidism — epidemiology, mortality and risk of complications. Clin. Endocrinol (Oxf.). 2016;84(6):904–911. https://doi.org/10.1111/cen.12948Vatta M., Ackerman M.J., Ye B., Makielski J.C., Ughanze E.E., Taylor E.W., et al. Mutant caveolin­3 induces persistent late sodium current and is associated with long­QT syndrome. Circulation. 2006;114(20):2104–2112. https://doi.org/10.1161/CIRCULATIONAHA.106.635268Vatta M., Ackerman M.J., Ye B., Makielski J.C., Ughanze E.E., Taylor E.W., et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation. 2006;114(20):2104–2112. https://doi.org/10.1161/CIRCULATIONAHA.106.635268Viskin S., Postema P.G., Bhuiyan Z.A., Rosso R., Kalman J.M., Vohra J.K., et al. Te response of the QT interval to the brief tachycardia provoked by standing: A bedside test for diagnosing long QT syndrome. J. Am. Coll. Cardiol. 2010;55(18):1955–1961. https://doi.org/10.1016/j.jacc.2009.12.015Viskin S., Postema P.G., Bhuiyan Z.A., Rosso R., Kalman J.M., Vohra J.K., et al. The response of the QT interval to the brief tachycardia provoked by standing: A bedside test for diagnosing long QT syndrome. J. Am. Coll. Cardiol. 2010;55(18):1955–1961. https://doi.org/10.1016/j.jacc.2009.12.015World Anti­Doping Agency. Prohibited List, Yanuary 2016 [Internet]. Available at: https://www.fa.com/sites/default/fles/wada­2016­prohibited­list­en_0.pdf (accessed April 24, 2016).World Anti-Doping Agency. Prohibited List, Yanuary 2016 [Internet]. Available at: https://www.fia.com/sites/default/files/wada-2016-prohibited-list-en_0.pdf (accessed April 24, 2016).Wedekind H., Burde D., Zumhagen S., Debus V., Burkhardtsmaier G., Mönnig G., Breithardt G., Schulze-Bahr E. QT interval prolongation and risk for cardiac events in genotyped LQTS­index children. Eur. J. Pediatr. 2009;168(9):1107–1115. https://doi.org/10.1007/s00431­008­0896­6Wedekind H., Burde D., Zumhagen S., Debus V., Burkhardtsmaier G., Mönnig G., Breithardt G, Schulze-Bahr E. QT interval prolongation and risk for cardiac events in genotyped LQTS-index children. Eur. J. Pediatr. 2009;168(9):1107–1115. https://doi.org/10.1007/s00431-008-0896-6Zipes D.P., Ackerman M.J., Estes N.A. 3rd, Grant A.O., Myerburg R.J., Van Hare G. Task Force 7: arrhythmias. J. Am. Coll. Cardiol. 2005;45(8):1354–1363. https://doi.org/10.1016/j.jacc.2005.02.014Zipes D.P., Ackerman M.J., Estes N.A. 3rd, Grant A.O., Myerburg R.J., Van Hare G. Task Force 7: arrhythmias. J. Am. Coll. Cardiol. 2005;45(8):1354–1363. https://doi.org/10.1016/j.jacc.2005.02.014

The authors declare that there are no conflicts of interest present.